Development and<i>in vitro</i>safety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Tzankov, Borislav; Voycheva, Christina; Yordanov, Yordan; Aluani, Denitsa; Spassova, Ivanka; Kovacheva, Daniela; Lambov, Nikolay; Tzankova, Virginia

doi:10.1080/13102818.2019.1649094

Cited by 18 publications

(20 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formulation 1, referred to as the PVA-PDM formulation, consisted of 5% ( w / w ) pramipexole dihydrochloride monohydrate (PDM, Chr. Olesen, Denmark) as an API of the biopharmaceutics classification system (BCS) class I, declared as good water solubility (c s ≥ 200 mg/mL) [ 49 , 50 ]. Mannitol (Parteck M ® , Merck, Germany) was used as a plasticizer at 10% ( w / w ) content.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…baskets, except that the mesh width was changed to 3 mm. The dissolution test for PDM containing tablets was performed in 500 mL of degassed 0.1 N hydrochloric acid at pH 1.2 under sink conditions (c s ≥ 200 mg/mL [50]; maximum concentration 0.08 mg/mL) and stirred at 50 rpm at a temperature of 37 ± 0.5 • C. The released API was measured using an UV-Vis spectral photometer (UV-1800 Shimadzu, Japan) at a wavelength of 263 nm. Dissolution testing of the levodopa containing geometries was performed in 1000 mL of degassed 0.1 N hydrochloric acid at pH 1.2 under sink conditions (c s ≥ 12 mg/mL [51]; maximum concentration 0.05 mg/mL) and stirred at 50 rpm at a temperature of 37 ± 0.5 • C. The API release was recorded with the same UV-Vis spectral photometer at a wavelength of 280 nm.…”

Section: D Printing Of Tabletsmentioning

confidence: 99%

See 2 more Smart Citations

Predicting Drug Release from 3D Printed Oral Medicines Based on the Surface Area to Volume Ratio of Tablet Geometry

2021

View full text Add to dashboard Cite

3D printing offers the advantage of being able to modify dosage form geometry, which can be exploited to modify release characteristics. In this study, we investigated the influence of the surface area to volume ratio (SA/V) to change and predict release profiles of 3D printed dosage forms. Geometries with varying SA/V and dosages were designed and printed, and drug dissolution was investigated. Three drug substances were used: pramipexole, levodopa (both BCS I) and praziquantel (BCS II). Two polymers were chosen as matrix formers: polyvinyl alcohol (water-soluble) and ethylene vinyl acetate (inert). Drug release was characterized using the mean dissolution time (MDT) and established equations that describe complete dissolution curves were applied. Predictions were validated with previously un-printed dosage forms. Based on an identified MDT-SA/V correlation, the MDT can be predicted with a deviation of ≤5 min for a given SA/V. Using correlations of fit parameters and SA/V, RMSEP values of 0.6–2.8% and 1.6–3.4% were obtained for the BCS I formulations and RMSEP values of 1.0–3.8% were obtained for the BCS II formulation, indicating accurate prediction over a wide range of dissolution profiles. With this approach, MDT and release profiles of dosage forms with a given SA/V can be precisely predicted without performing dissolution tests and vice versa, the required SA/V can be predicted for a desired release profile.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: D Printing Of Tabletsmentioning

confidence: 99%

See 1 more Smart Citation

Predicting Drug Release from 3D Printed Oral Medicines Based on the Surface Area to Volume Ratio of Tablet Geometry

2021

View full text Add to dashboard Cite

show abstract

“…Cytotoxicity assay results suggested that the toxicity of the free drug was greatly reduced upon encapsulation in coated MSNs, and the designed drug delivery system showed promising potential in preventing H 2 O 2 -induced oxidative damage in human neuroblastoma SH-SY5Y cells [47]. The same group later demonstrated the ability of chitosan and sodium alginate coated hollow MSNs for the delivery of dopamine-receptor agonist pramipexole [68].…”

Section: Polymer Coated Msns For Neurodegenerative Diseasesmentioning

confidence: 96%

Therapeutic Potential of Polymer-Coated Mesoporous Silica Nanoparticles

et al. 2019

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSNs) find tremendous applications in drug delivery due to several advantages such as their easy fabrication process, high drug loading, biodegradability, biocompatibility, and so forth. Nevertheless, despite several advantages, the use of this striking drug delivery carrier is restricted due to premature drug release owing to the porous structure. Coating of the pores using polymers has emerged as a great solution to this problem. Polymer coatings, which act as gatekeepers, avoid the premature release of loaded content from MSNs and offers the opportunity for controlled and targeted drug delivery. Therefore, in this review, we have compiled the polymer-based coating approaches used in recent years for improving the drug delivery capability of MSNs. This manuscript provides an insight into the research about the potential of polymer-coated MSNs, allowing the selection of right polymer for coating purposes according to the desired application.

show abstract

“…In vitro drug release studies have demonstrated a sustained release pattern at both intestinal and gastric pH values. In addition, no hemolysis was found for HMS-pramipexole NPs, and SH-SY5Y treatment resulted in a better antioxidant protection effect when compared with pramipexole alone [ 121 ]. In the same year, Tzankov and his team developed another type of mesoporous silica NP (MCM-41) to incorporate into pramipexole for oral administration.…”

Section: Nanoparticles As Drug Delivery System Repurposing In Pdmentioning

confidence: 99%

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs

2021

View full text Add to dashboard Cite

Parkinson’s disease (PD) affects around ten million people worldwide and is considered the second most prevalent neurodegenerative disease after Alzheimer’s disease. In addition, there is a higher risk incidence in the elderly population. The main PD hallmarks include the loss of dopaminergic neurons and the development of Lewy bodies. Unfortunately, motor symptoms only start to appear when around 50–70% of dopaminergic neurons have already been lost. This particularly poses a huge challenge for early diagnosis and therapeutic effectiveness. Actually, pharmaceutical therapy is able to relief motor symptoms, but as the disease progresses motor complications and severe side-effects start to appear. In this review, we explore the research conducted so far in order to repurpose drugs for PD with the use of nanodelivery systems, alternative administration routes, and nanotheranostics. Overall, studies have demonstrated great potential for these nanosystems to target the brain, improve drug pharmacokinetic profile, and decrease side-effects.

show abstract

Development andin vitrosafety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Abstract: View related articles View Crossmark data Citing articles: 1 View citing articles Development and in vitro safety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

Cited by 18 publications

References 69 publications

Predicting Drug Release from 3D Printed Oral Medicines Based on the Surface Area to Volume Ratio of Tablet Geometry

Predicting Drug Release from 3D Printed Oral Medicines Based on the Surface Area to Volume Ratio of Tablet Geometry

Therapeutic Potential of Polymer-Coated Mesoporous Silica Nanoparticles

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs

Contact Info

Product

Resources

About